STUDY REPORT
Insights from a Quest Diagnostics Feasibility Study Conducted with Proscia and Ibex Medical Analytics
In a recent collaboration, Quest, Ibex, and Proscia ran a feasibility study* designed to understand how AI-powered diagnostics, delivered through an enterprise digital pathology platform, would impact operations in a large diagnostic lab setting. An overview of the results showed that:
- Deeply integrated AI-powered workflows drive lab efficiency, allowing pathologists to sign out 2.9 cases per hour instead of 1.2.
- Digital pathology is easy to use and learn, and pathologists are eager to adopt Proscia’s Concentriq® with Ibex Prostate.
- Ibex Prostate is highly accurate in detecting cancer and other pathologies, and in alignment with the accuracy of the pathologists’ diagnoses.
Download the full report to dive deeper into the study goals, methodology, and results.
Read the report to find out how AI-powered digital pathology can transforming routine diagnostic practice.
Figure 1: Example of digitized slide of a PCNB tissue sample (WSI) for review in the Concentriq Dx DP workflow (no AI overlay).
Figure 2: Example of digitized slide of a PCNB tissue sample (WSI) in the Concentriq Dx DP workflow with Ibex Prostate AI overlay highlighting the high cancer likelihood areas.
About Proscia
Proscia is a software company accelerating pathology’s transition to digital to change the way we understand diseases like cancer. Its Concentriq enterprise pathology platform and powerful AI applications are unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision medicine.